Zai Lab (ZLAB) Scheduled to Post Earnings on Wednesday

Zai Lab (NASDAQ:ZLAB) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The firm had revenue of $65.83 million for the quarter, compared to the consensus estimate of $70.41 million. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Price Performance

NASDAQ:ZLAB opened at $16.25 on Monday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -4.71 and a beta of 1.11. Zai Lab has a 1 year low of $13.48 and a 1 year high of $39.50. The stock’s 50 day simple moving average is $17.07 and its two-hundred day simple moving average is $22.25.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ZLAB shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Friday, January 12th. Citigroup decreased their target price on shares of Zai Lab from $123.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $64.22.

Insider Buying and Selling at Zai Lab

In related news, insider Rafael Amado sold 2,544 shares of Zai Lab stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $18.86, for a total transaction of $47,979.84. Following the completion of the transaction, the insider now directly owns 20,093 shares of the company’s stock, valued at approximately $378,953.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Joshua L. Smiley sold 1,988 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total transaction of $31,151.96. Following the completion of the sale, the insider now directly owns 28,684 shares of the company’s stock, valued at $449,478.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rafael Amado sold 2,544 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $18.86, for a total transaction of $47,979.84. Following the completion of the transaction, the insider now owns 20,093 shares in the company, valued at $378,953.98. The disclosure for this sale can be found here. Insiders have sold 12,568 shares of company stock worth $208,508 over the last quarter. Insiders own 5.23% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.